X0508 4 2025-12-16 0 0001541157 Akari Therapeutics Plc AKTX 0002093620 Farag Kameel D. C/O AKARI THERAPEUTICS PLC 401 EAST JACKSON STREET, SUITE 3300 TAMPA FL 33602 0 1 0 0 Interim CFO 0 Warrants to purchase American Depositary Shares ("ADRs") 0.3883 2025-12-16 4 P 0 24745 A American Depositary Shares representing Ordinary Shares 24745 24745 D Pre-Funded Warrants to purchase ADRs 0.0000 2025-12-16 4 P 0 24745 0.4041 A American Depositary Shares representing Ordinary Shares 24745 24745 D Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 24,745 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 24,745 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised. The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. Conversion Exercise Price of Security is $0.00001 /s/ Abizer Gaslightwala, as Attorney-in-Fact 2025-12-18